FDA Approves First-Ever Treatment for Thyroid Eye Disease
The Food and Drug Administration (FDA) announced on Tuesday that it had just approved the first-ever treatment for thyroid eye disease (TED), Tepezza, which is developed by Horizon Therapeutics (NASDAQ: HZNP).
Thyroid eye disease, also known as Graves' ophthalmopathy, is a rare disease that, according to some sources, affects as many as 42 people per 100,000 every year. This rare condition causes the tissues behind the eye to become inflamed, which results in the eye becoming red and swollen, and causes severe problems such as double vision.
Image source: Getty Images.
Source Fool.com
